Dr. Tracey’s research discoveries have been guiding principles for Inmedix since its inception.
NORMANDY PARK, WA, USA, May 3, 2023/EINPresswire.com/ — Seattle-based medtech/biotech Inmedix, Inc., developers of immuno-autonomics and cloud-based clinical diagnostics to quantify stress biology with precision, announced today the addition of Kevin J. Tracey MD to its Board of Directors.
Dr. Tracey is President and CEO of the Feinstein Institute in New York and the Karches Family Distinguished Chair in Medical Research at the Feinstein Institutes for Medical Research; professor of Molecular Medicine and Neurosurgery at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell; and Executive Vice President, Research, at Northwell Health. A leader in the scientific fields of inflammation and bioelectronic medicine, his contributions include discovery and molecular mapping of neural circuits controlling immunity.
Dr. Tracey received his BS in chemistry, summa cum laude, Phi Beta Kappa, from Boston College in 1979, and his MD from Boston University in 1983. He trained in neurosurgery from 1983 to 1992 at the New York Hospital-Cornell University Medical Center and was a guest investigator at the Rockefeller University before moving in 1992 to the Feinstein Institutes. There he directs the Laboratory of Biomedical Science and was appointed president and CEO in 2005.
An inventor of more than 120 United States patents and author of more than 400 scientific publications, he cofounded the Global Sepsis Alliance, a non-profit organization supporting the efforts of more than 1 million sepsis caregivers in over 70 countries. Dr. Tracey is the author of Fatal Sequence (Dana Press) and delivers lectures nationally and internationally on inflammation, sepsis, the neuroscience of immunity, and bioelectronic medicine.
“The link between the brain and the immune system is fundamental,” said Dr. Tracey. “I am eager to engage in this exceptional opportunity with Dr. Holman and Inmedix to advance our understanding of human physiology and to apply innovation to improve patient care.”
Inmedix is defining the emerging medical field of immuno-autonomics: the interface between immune function and stress biology, controlled within the brain by the autonomic nervous system (ANS). The natural stress response can beneficially impact immune function in the near term (1). However, chronic activation of the immune system by stress, mediated by the ANS, has been implicated in adversely affecting the onset and severity of autoimmune disease (2). With its CloudHRV diagnostic in development, Inmedix intends to provide the leading, precision tool to quantify ANS stress state to support research and clinical care.
“I expect Dr. Tracey’s discovery of the cholinergic anti-inflammatory reflex (3) to transform medicine by recognizing fundamental connections between the brain’s autonomic nervous system (ANS) and the immune system,” said Inmedix CEO & Co-founder Andrew J Holman, MD. “Ever since I witnessed his standing-room-only presentation at the annual meeting of the American College of Rheumatology (ACR) in 2004 titled “Mind over Immunity”, his research in medicine has been a guiding light to mine.”
1. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve – an integrative interface
between two supersystems: the brain and the immune system. Pharmacol Rev 2000;52:595-
2. Taylor PC, Holman A J. Rheumatoid arthritis and the emergence of immuno-autonomics.
Rheumatology (Oxford). 2019 Dec 1;58(12):2079-2080. doi: 10.1093/rheumatology/kez216. PMID:
3. Tracey KJ. The inflammatory reflex. Nature 2002;420:853-859.
About Inmedix, Inc. and its subsidiary, Inmedix UK, Ltd.
Seattle-based biotech/medtech Inmedix, Inc. and its subsidiary Inmedix UK, Ltd., are committed to engaging in world class research to discover innovative solutions for pressing healthcare needs related to the impact of stress, modulated within the brain by the autonomic nervous system (ANS). The Inmedix® CloudHRV diagnostic system is leading the development of heart rate variability (HRV) as a potentially informative diagnostic, therapeutic, digital health, and health economic tool. ANS profile may be the most overlooked element of personalized, precision medicine. Beginning with rheumatoid arthritis (RA), psoriatic arthritis (PsA), systemic lupus erythematosus (SLE) and ankylosing spondylitis (AS) in adults, the company hopes to understand and validate the role of stress biology in immunology.
This press release contains certain forward-looking statements, including without limitation statements regarding Inmedix’s plans for preclinical studies and product capabilities. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Inmedix’s business which could significantly affect expected results, including without limitation, progress of development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Inmedix undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release. This is not an offer to sell or an offer to purchase securities.
For more information, visit http://www.inmedix.com
email us here
Article originally published on www.einpresswire.com as Inmedix welcomes Kevin J. Tracey, MD, to its Board of Directors